Cystic Fibrosis News

Although inhaled antisense oligonucleotide treatment is safe, its efficacy needs to be determined in patients with the cystic fibrosis splicing mutation 3849+10kb C-to-T, according to a press release from the Cystic Fibrosis Foundation.

It is known that persons with cystic fibrosis are more susceptible to infections; however, the impact of elexacaftor/tezacaftor/ivacaftor therapy on this susceptibility has not been well studied yet.

When asked about newborn screening tests, nearly half of surveyed parents with a young child did not know the conditions included on these tests, according to results presented at the Pediatric Academic Societies Meeting.

With the recent addition of two pediatric pulmonologists, the Cystic Fibrosis Center at Children’s Hospital Los Angeles continues to advance research on this disease, especially for children from diverse racial and ethnic backgrounds.

In addition to suffering with cystic fibrosis, patients with this condition often contract lung infections that are difficult to treat; however, an upcoming study may reveal a way to lower infection prevalence.

Patients with cystic fibrosis frequently experience bacterial infections, but a zinc transport protein may be able to lower infection incidence, according to findings published in Proceedings of the National Academy of Sciences.

Patients with cystic fibrosis had reduced lung function if they had at least one 12-month or longer gap in receiving care, according to findings published in Annals of the American Thoracic Society.

In patients with cystic fibrosis, a new genetic technology could permanently fix the CF transmembrane conductance regulator gene in hundreds of disease-causing CF mutations, according to a press release from the Cystic Fibrosis Foundation.

In patients aged 6 to 21 years with cystic fibrosis receiving pulmonary exacerbation treatment, changing antibiotics was not clinically beneficial, according to results published in Annals of the American Thoracic Society.